Allena Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ALNA)

$7.31 +0.05 (+0.69 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$7.31
Today's Range$7.15 - $7.72
52-Week Range$6.15 - $15.40
Volume116,406 shs
Average Volume59,840 shs
Market Capitalization$150.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals logoAllena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577

Debt

Debt-to-Equity Ratio-0.09%
Current Ratio4.83%
Quick Ratio4.83%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees27
Outstanding Shares20,670,000

Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals Inc (NASDAQ:ALNA) released its earnings results on Thursday, December, 14th. The company reported ($3.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $3.11. View Allena Pharmaceuticals' Earnings History.

Where is Allena Pharmaceuticals' stock going? Where will Allena Pharmaceuticals' stock price be in 2018?

4 Wall Street analysts have issued 1-year price objectives for Allena Pharmaceuticals' stock. Their predictions range from $22.00 to $30.00. On average, they anticipate Allena Pharmaceuticals' share price to reach $24.67 in the next year. View Analyst Ratings for Allena Pharmaceuticals.

What are Wall Street analysts saying about Allena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (2/13/2018)
  • 2. Wedbush analysts commented, "We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset." (12/18/2017)

Who are some of Allena Pharmaceuticals' key competitors?

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the folowing people:

  • Louis Brenner M.D., President, Chief Operating Officer (Age 44)
  • Alexey L. Margolin Ph.D., Chief Executive Officer, Co-Founder, Director (Age 63)
  • Hugh Wight, Vice President - Technical Operations
  • Stephen Kraus, Director (Age 38)
  • Bob Tepper M.D., Director

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

When does the company's lock-up period expire?

Allena Pharmaceuticals' lock-up period expires on Tuesday, May 1st. Allena Pharmaceuticals had issued 5,333,333 shares in its public offering on November 2nd. The total size of the offering was $74,666,662 based on an initial share price of $14.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

Who owns Allena Pharmaceuticals stock?

Allena Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Frazier Management LLC (16.11%), Sphera Funds Management LTD. (1.57%), Perceptive Advisors LLC (1.21%), BlackRock Inc. (1.10%), Goldman Sachs Group Inc. (0.24%) and Millennium Management LLC (0.11%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals.

Who bought Allena Pharmaceuticals stock? Who is buying Allena Pharmaceuticals stock?

Allena Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Frazier Management LLC, Sphera Funds Management LTD., Perceptive Advisors LLC, BlackRock Inc., Goldman Sachs Group Inc., Millennium Management LLC, Needham Investment Management LLC and Deutsche Bank AG. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.

How do I buy Allena Pharmaceuticals stock?

Shares of Allena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of Allena Pharmaceuticals stock can currently be purchased for approximately $7.31.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $150.07 million. Allena Pharmaceuticals employs 27 workers across the globe.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.


MarketBeat Community Rating for Allena Pharmaceuticals (ALNA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Allena Pharmaceuticals (NASDAQ:ALNA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 3.003.00N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.67$24.67N/AN/A
Price Target Upside: 140.65% upside140.65% upsideN/AN/A

Allena Pharmaceuticals (NASDAQ:ALNA) Consensus Price Target History

Price Target History for Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals (NASDAQ:ALNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017WedbushReiterated RatingBuyMediumView Rating Details
11/27/2017CowenInitiated CoverageOutperformHighView Rating Details
11/27/2017Jefferies GroupInitiated CoverageBuy$22.00HighView Rating Details
11/27/2017Credit Suisse GroupInitiated CoverageOutperform$22.00HighView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Allena Pharmaceuticals (NASDAQ:ALNA) Earnings History and Estimates Chart

Earnings by Quarter for Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals (NASDAQ ALNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/14/2017Q3 2017($0.38)($3.49)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Allena Pharmaceuticals (NASDAQ:ALNA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.48)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.37)($0.37)($0.37)
Q2 20181($0.37)($0.37)($0.37)
Q3 20181($0.37)($0.37)($0.37)
Q4 20181($0.37)($0.37)($0.37)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Allena Pharmaceuticals (NASDAQ:ALNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Allena Pharmaceuticals (NASDAQ ALNA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.07%
Insider Trades by Quarter for Allena Pharmaceuticals (NASDAQ:ALNA)
Institutional Ownership by Quarter for Allena Pharmaceuticals (NASDAQ:ALNA)

Allena Pharmaceuticals (NASDAQ ALNA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/6/2017Bessemer Venture Partners ViiMajor ShareholderBuy36,000$14.00$504,000.00View SEC Filing  
11/6/2017James N TopperDirectorBuy500,000$14.00$7,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Allena Pharmaceuticals (NASDAQ ALNA) News Headlines

Source:
DateHeadline
Pharmstandard International S.A. Buys Allena Pharmaceuticals IncPharmstandard International S.A. Buys Allena Pharmaceuticals Inc
finance.yahoo.com - February 15 at 8:39 AM
Jefferies Group Weighs in on Allena Pharmaceuticals Incs FY2017 Earnings (ALNA)Jefferies Group Weighs in on Allena Pharmaceuticals Inc's FY2017 Earnings (ALNA)
www.americanbankingnews.com - February 15 at 7:56 AM
Allena Pharmaceuticals Inc (ALNA) Given Consensus Rating of "Hold" by AnalystsAllena Pharmaceuticals Inc (ALNA) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 13 at 5:52 PM
Allena Pharmaceuticals (ALNA) Downgraded to "Sell" at Zacks Investment ResearchAllena Pharmaceuticals (ALNA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 13 at 4:16 PM
Wedbush Comments on Allena Pharmaceuticals Incs FY2022 Earnings (ALNA)Wedbush Comments on Allena Pharmaceuticals Inc's FY2022 Earnings (ALNA)
www.americanbankingnews.com - February 9 at 6:30 PM
 Analysts Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA) Analysts Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - February 1 at 1:28 AM
 Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) to Post -$0.33 Earnings Per Share Analysts Anticipate Allena Pharmaceuticals Inc (ALNA) to Post -$0.33 Earnings Per Share
www.americanbankingnews.com - January 18 at 7:14 AM
 Brokerages Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA) Brokerages Set $26.00 Price Target for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - January 17 at 5:42 AM
Zacks: Analysts Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)Zacks: Analysts Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - January 2 at 9:42 PM
Comparing Allena Pharmaceuticals (ALNA) & The CompetitionComparing Allena Pharmaceuticals (ALNA) & The Competition
www.americanbankingnews.com - December 20 at 9:28 PM
Wedbush Equities Analysts Increase Earnings Estimates for Allena Pharmaceuticals Inc (ALNA)Wedbush Equities Analysts Increase Earnings Estimates for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - December 20 at 9:56 AM
Wedbush Reaffirms Buy Rating for Allena Pharmaceuticals (ALNA)Wedbush Reaffirms Buy Rating for Allena Pharmaceuticals (ALNA)
www.americanbankingnews.com - December 18 at 8:26 PM
 Brokerages Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA) Brokerages Set $26.00 Target Price for Allena Pharmaceuticals Inc (ALNA)
www.americanbankingnews.com - December 15 at 5:52 AM
Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateAllena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - December 14 at 8:12 AM
Allena Pharmaceuticals, Inc.s Quiet Period To End  on December 12th (NASDAQ:ALNA)Allena Pharmaceuticals, Inc.'s Quiet Period To End on December 12th (NASDAQ:ALNA)
www.americanbankingnews.com - December 5 at 1:32 AM
Equities Analysts Offer Predictions for Allena Pharmaceuticals, Inc.s Q3 2017 Earnings (ALNA)Equities Analysts Offer Predictions for Allena Pharmaceuticals, Inc.'s Q3 2017 Earnings (ALNA)
www.americanbankingnews.com - November 30 at 5:58 AM
Allena Pharmaceuticals, Inc. (ALNA) Forecasted to Earn Q3 2017 Earnings of ($0.30) Per ShareAllena Pharmaceuticals, Inc. (ALNA) Forecasted to Earn Q3 2017 Earnings of ($0.30) Per Share
www.americanbankingnews.com - November 29 at 7:34 AM
Zacks: Allena Pharmaceuticals, Inc. (ALNA) Given $22.00 Average Price Target by AnalystsZacks: Allena Pharmaceuticals, Inc. (ALNA) Given $22.00 Average Price Target by Analysts
www.americanbankingnews.com - November 28 at 9:24 AM
Allena Pharmaceuticals, Inc. (ALNA) Now Covered by Analysts at Jefferies Group LLCAllena Pharmaceuticals, Inc. (ALNA) Now Covered by Analysts at Jefferies Group LLC
www.americanbankingnews.com - November 27 at 6:50 PM
Allena Pharmaceuticals, Inc. (ALNA) Coverage Initiated at WedbushAllena Pharmaceuticals, Inc. (ALNA) Coverage Initiated at Wedbush
www.americanbankingnews.com - November 27 at 8:36 AM
Cowen Inc Initiates Coverage on Allena Pharmaceuticals, Inc. (ALNA)Cowen Inc Initiates Coverage on Allena Pharmaceuticals, Inc. (ALNA)
www.americanbankingnews.com - November 27 at 8:36 AM
Allena Pharmaceuticals, Inc. (ALNA) Receives New Coverage from Analysts at Credit Suisse GroupAllena Pharmaceuticals, Inc. (ALNA) Receives New Coverage from Analysts at Credit Suisse Group
www.americanbankingnews.com - November 27 at 7:58 AM
Allena Pharmaceuticals stock falls in its public debutAllena Pharmaceutical's stock falls in its public debut
finance.yahoo.com - November 24 at 2:48 PM
Allena Pharmaceuticals Inc (ALNA): Time For A Financial Health CheckAllena Pharmaceuticals Inc (ALNA): Time For A Financial Health Check
finance.yahoo.com - November 24 at 2:48 PM
What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?
finance.yahoo.com - November 24 at 2:48 PM
Allena Pharmaceuticals Inc (ALNA) Major Shareholder Bessemer Venture Partners Vii Buys 36,000 SharesAllena Pharmaceuticals Inc (ALNA) Major Shareholder Bessemer Venture Partners Vii Buys 36,000 Shares
www.americanbankingnews.com - November 6 at 9:20 PM
Allena Pharmaceuticals Inc (ALNA) Director James N. Topper Purchases 500,000 SharesAllena Pharmaceuticals Inc (ALNA) Director James N. Topper Purchases 500,000 Shares
www.americanbankingnews.com - November 6 at 9:20 PM
Allena Pharmaceuticals (ALNA) Announces November 2nd IPOAllena Pharmaceuticals (ALNA) Announces November 2nd IPO
www.americanbankingnews.com - October 25 at 1:04 AM

SEC Filings

Allena Pharmaceuticals (NASDAQ:ALNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Allena Pharmaceuticals (NASDAQ:ALNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Allena Pharmaceuticals (NASDAQ ALNA) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.